HC Wainwright Reiterates “Buy” Rating for Coherus BioSciences (NASDAQ:CHRS)
Coherus BioSciences (NASDAQ:CHRS – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company’s stock. Separately, Robert W. Baird lifted their price objective on shares of Coherus BioSciences from $4.00 to $6.00 […]
Coherus BioSciences (NASDAQ:CHRS – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company’s stock. Separately, Robert W. Baird lifted their price objective on shares of Coherus BioSciences from $4.00 to $6.00 […]
